Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Positron Emission Tomography Imaging of Participants With Known or Suspected Neuroendocrine Tumours Using 64Cu SARTATE: A Multi-Centre, Single Arm, Non-Randomised, Blinded-Review, Phase II Study

NCT04438304 is registered in ClinicalTrials.gov with Clarity Pharmaceuticals Ltd as lead sponsor.

NCT NCT04438304
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04438304 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Positron Emission Tomography Imaging of Participants With Known or Suspected Neuroendocrine Tumours Using 64Cu SARTATE: A Multi-Centre, Single Arm, Non-Randomised, Blinded-Review, Phase II Study
Lead sponsor
Clarity Pharmaceuticals Ltd
Phase
Phase 2
Overall status
Completed
Start date
March 2, 2021
Completion date
November 26, 2024
Enrollment
45 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

neuroendocrine tumors